Gastric GE Trials

TRIO-US AstraZeneca D910GC00001 “Matterhorn”

A Randomized, Double-blind, Placebo-controlled, Phase III Study
of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy
Followed by Adjuvant Durvalumab in Patients with Resectable
Gastric and Gastroesophageal Junction Cancer (GC/GEJC)

Fort Wayne North Office
(260) 484-8830
2514 E Dupont Road, Suite 100
Fort Wayne, IN 46825

Fort Wayne South Office
(260) 436-0800
7910 West Jefferson Boulevard, Suite 108
Fort Wayne, Indiana 46804

©2019 Fort Wayne Medical Oncology and Hematology. All Rights Reserved.